Elena V. Moroz-Omori

Elena V. Moroz-Omori

Auto-generated profile, based on publicly available information

Elena V. Moroz-Omori

Moscow State University

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
EMElena Moroz
Elena Moroz
SMSimon Matoori
Simon Matoori
JLJean-Christophe Leroux
Jean-Christophe Leroux

8 July 2021 in ChemMedChem
Verified
Journal Article
Open access
PDF file
EMElena V. Moroz‐Omori
Elena V. Moroz‐Omori
DHDanzhi Huang
Danzhi Huang
RBRajiv Kumar Bedi
Rajiv Kumar Bedi
SCSherry J. Cheriyamkunnel
Sherry J. Cheriyamkunnel
EBElena Bochenkova
Elena Bochenkova
ACAmedeo Caflisch
Amedeo Caflisch
The methylase METTL3 is the writer enzyme of the N6‐methyladenosine (m6A) modification of RNA. Using a structure‐based drug discovery approach, we identified a METTL3 inhibitor with potency in a biochemical assay of 280 nM, while its enantiomer is 100 times less active. We observed a dose‐dependent reduction in the m6A methylation level of mRNA in several cell lines treated with the inhibitor already after 16 h of treatment, which lasted for at least 6 days. Importantly, the prolonged incubation (up to 6 days) with the METTL3 inhibitor did not alter levels of other RNA modifications (i. e., m1A, m6Am, m7G), suggesting selectivity of the developed compound towards other RNA methyltransferases.

25 August 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
ADAymeric Dolbois
Aymeric Dolbois
RBRajiv K. Bedi
Rajiv K. Bedi
EBElena Bochenkova
Elena Bochenkova
AMAnna Müller
Anna Müller
EMElena V. Moroz-Omori
Elena V. Moroz-Omori
ACAmedeo Caflisch
Amedeo Caflisch
N6-methyladenosine (m6A) is the most frequent of the 160 RNA modifications reported so far. Accumulating evidence suggests that the METTL3/METTL14 protein complex, part of the m6A regulation machinery, is a key player in a variety of diseases including several types of cancer, type 2 diabetes, and viral infections. Here we report on a protein crystallography-based medicinal chemistry optimization of a METTL3 hit compound that has resulted in a 1400-fold potency improvement (IC50 of 5 nM for the lead compound 22 (UZH2) in a time-resolved Förster resonance energy transfer (TR-FRET) assay). The series has favorable ADME properties as physicochemical characteristics were taken into account during hit optimization. UZH2 shows target engagement in cells and is able to reduce the m6A/A level of polyadenylated RNA in MOLM-13 (acute myeloid leukemia) and PC-3 (prostate cancer) cell lines.

4 September 2014 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
SLSoo Hyeon Lee
Soo Hyeon Lee
EMElena Moroz
Elena Moroz
BCBastien Castagner
Bastien Castagner
JLJean-Christophe Leroux
Jean-Christophe Leroux

1 April 2020 in ACS Central Science
Verified
Journal Article
Open access
EMElena V. Moroz-Omori
Elena V. Moroz-Omori
DSDwiantari Satyapertiwi
Dwiantari Satyapertiwi
MRMarie-Christine Ramel
Marie-Christine Ramel
HHHåkon Høgset
Håkon Høgset
ISIlona K. Sunyovszki
Ilona K. Sunyovszki
MSMolly M. Stevens
Molly M. Stevens
The recently discovered CRISPR-Cas gene editing system and its derivatives have found numerous applications in fundamental biology research and pharmaceutical sciences. The need for precise external control over the gene editing and regulatory events has driven the development of inducible CRISPR-Cas systems. While most of the light-controllable CRISPR-Cas systems are based on protein engineering, we developed an alternative synthetic approach based on modification of crRNA/tracrRNA duplex (guide RNA or gRNA) with photocaging groups, preventing the gRNA from recognizing its genome target sequence until its deprotection is induced within seconds of illumination. This approach relies on a straightforward solid-phase synthesis of the photocaged gRNAs, with simpler purification and characterization processes in comparison to engineering a light-responsive protein. We have demonstrated the feasibility of photocaging of gRNAs and light-mediated DNA cleavage upon brief exposure to light in vitro. We have achieved light-mediated spatiotemporally resolved gene editing as well as gene activation in cells, whereas photocaged gRNAs showed virtually no detectable gene editing or activation in the absence of light irradiation. Finally, we have applied this system to spatiotemporally control gene editing in zebrafish embryos in vivo, enabling the use of this strategy for developmental biology and tissue engineering applications.

19 October 2020 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
YLYaozong Li
Yaozong Li
RBRajiv K. Bedi
Rajiv K. Bedi
EMElena V. Moroz-Omori
Elena V. Moroz-Omori
ACAmedeo Caflisch
Amedeo Caflisch